DDInter1938 DDInter1024
Vincristine is a vinca alkaloid with formula C46H56N4O10 found in the Madagascar periwinkle, Catharanthus roseus. It is used (commonly as the corresponding sulfate salt)as a chemotherapy drug for the treatment of leukaemia, lymphoma, myeloma, breast cancer and head and neck cancer. It has a role as a tubulin modulator, a microtubule-destabilising agent, a plant metabolite, an antineoplastic agent and a drug. It is a methyl ester, an acetate ester, a tertiary alcohol, a member of formamides, an organic heteropentacyclic compound, an organic heterotetracyclic compound, a tertiary amino compound and a vinca alkaloid. It is a conjugate base of a vincristine(2+). It derives from a hydride of a vincaleukoblastine.
Lapatinib is an anti-cancer drug developed by GlaxoSmithKline (GSK) as a treatment for solid tumours such as breast and lung cancer. It was approved by the FDA on March 13, 2007, for use in patients with advanced metastatic breast cancer in conjunction with the chemotherapy drug capecitabine. Lapatinib is a human epidermal growth factor receptor type 2 (HER2/ERBB2) and epidermal growth factor receptor (HER1/EGFR/ERBB1) tyrosine kinases inhibitor. It binds to the intracellular phosphorylation domain to prevent receptor autophosphorylation upon ligand binding.
Vincristine {u} (Compound) binds {v} (Gene) ABCB1
ABCB1 {u} (Gene) is bound by {v} (Compound) Lapatinib
Vincristine {u} (Compound) downregulates {v} (Gene) PIK3C2B
PIK3C2B {u} (Gene) is bound by {v} (Compound) Lapatinib
Vincristine {u} (Compound) downregulates {v} (Gene) EAPP
EAPP {u} (Gene) is upregulated by {v} (Compound) Lapatinib
Vincristine {u} (Compound) upregulates {v} (Gene) PLOD3
PLOD3 {u} (Gene) is downregulated by {v} (Compound) Lapatinib
Vincristine {u} (Compound) downregulates {v} (Gene) DUSP6
DUSP6 {u} (Gene) is downregulated by {v} (Compound) Lapatinib
Vincristine {u} (Compound) causes {v} (Side Effect) Leukopenia
Leukopenia {u} (Side Effect) is caused by {v} (Compound) Lapatinib
Vincristine {u} (Compound) resembles {v} (Compound) Vinblastine
Vinblastine {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Lapatinib
Vincristine {u} (Compound) binds {v} (Gene) ABCB1
ABCB1 {u} (Gene) is associated with {v} (Disease) breast cancer
breast cancer {u} (Disease) is treated by {v} (Compound) Lapatinib
Vincristine {u} (Compound) binds {v} (Gene) CYP3A5
CYP3A5 {u} (Gene) regulates {v} (Gene) HERC6
HERC6 {u} (Gene) is upregulated by {v} (Compound) Lapatinib
Vincristine {u} (Compound) downregulates {v} (Gene) PIK3C2B
PIK3C2B {u} (Gene) interacts with {v} (Gene) EGFR
EGFR {u} (Gene) is bound by {v} (Compound) Lapatinib
Vincristine (Compound) binds ABCB1 (Gene) and ABCB1 (Gene) is bound by Lapatinib (Compound)
Vincristine (Compound) downregulates PIK3C2B (Gene) and PIK3C2B (Gene) is bound by Lapatinib (Compound)
Vincristine (Compound) downregulates EAPP (Gene) and EAPP (Gene) is upregulated by Lapatinib (Compound)
Vincristine (Compound) upregulates PLOD3 (Gene) and PLOD3 (Gene) is downregulated by Lapatinib (Compound)
Vincristine (Compound) downregulates DUSP6 (Gene) and DUSP6 (Gene) is downregulated by Lapatinib (Compound)
Vincristine (Compound) causes Leukopenia (Side Effect) and Leukopenia (Side Effect) is caused by Lapatinib (Compound)
Vincristine (Compound) resembles Vinblastine (Compound) and Vinblastine may cause a moderate interaction that could exacerbate diseases when taken with Lapatinib
Vincristine (Compound) binds ABCB1 (Gene) and ABCB1 (Gene) is associated with breast cancer (Disease) and breast cancer (Disease) is treated by Lapatinib (Compound)
Vincristine (Compound) binds CYP3A5 (Gene) and CYP3A5 (Gene) regulates HERC6 (Gene) and HERC6 (Gene) is upregulated by Lapatinib (Compound)
Vincristine (Compound) downregulates PIK3C2B (Gene) and PIK3C2B (Gene) interacts with EGFR (Gene) and EGFR (Gene) is bound by Lapatinib (Compound)